These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 23590287)

  • 21. Numerical simulation of iontophoresis for in-silico prediction of transdermal drugs in the dermal layers using skin impedance values.
    Bora DJ; Dasgupta R
    Comput Methods Programs Biomed; 2022 Feb; 214():106551. PubMed ID: 34864336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review on skin targeted delivery of bioactives as ultradeformable vesicles: overcoming the penetration problem.
    Priyanka K; Singh S
    Curr Drug Targets; 2014 Feb; 15(2):184-98. PubMed ID: 24410447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conductivity of drugs used for iontophoresis.
    Gangarosa LP; Park NH; Fong BC; Scott DF; Hill JM
    J Pharm Sci; 1978 Oct; 67(10):1439-43. PubMed ID: 702299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Permeation enhancer strategies in transdermal drug delivery.
    Marwah H; Garg T; Goyal AK; Rath G
    Drug Deliv; 2016; 23(2):564-78. PubMed ID: 25006687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treprostinil Hydrogel Iontophoresis in Systemic Sclerosis-Related Digital Skin Ulcers: A Safety Study.
    Guigui A; Mazet R; Blaise S; Cracowski C; Beau-Guillaumot M; Kotzki S; Roustit M; Cracowski JL
    J Clin Pharmacol; 2020 Jun; 60(6):758-767. PubMed ID: 32080862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced transdermal delivery of indomethacin using combination of PLGA nanoparticles and iontophoresis in vivo.
    Tomoda K; Terashima H; Suzuki K; Inagi T; Terada H; Makino K
    Colloids Surf B Biointerfaces; 2012 Apr; 92():50-4. PubMed ID: 22154100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal iontophoresis of flufenamic acid loaded PLGA nanoparticles.
    Malinovskaja-Gomez K; Labouta HI; Schneider M; Hirvonen J; Laaksonen T
    Eur J Pharm Sci; 2016 Jun; 89():154-62. PubMed ID: 27131608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iontophoretic transdermal delivery using chitosan-coated PLGA nanoparticles for positively charged drugs.
    Takeuchi I; Takeshita T; Suzuki T; Makino K
    Colloids Surf B Biointerfaces; 2017 Dec; 160():520-526. PubMed ID: 29017147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced transdermal drug delivery techniques: an extensive review of patents.
    Rizwan M; Aqil M; Talegaonkar S; Azeem A; Sultana Y; Ali A
    Recent Pat Drug Deliv Formul; 2009 Jun; 3(2):105-24. PubMed ID: 19519571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AC electrokinetic platform for iontophoretic transdermal drug delivery.
    Lvovich VF; Matthews E; Riga AT; Kaza L
    J Control Release; 2010 Jul; 145(2):134-40. PubMed ID: 20420867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transdermal permeation of alniditan by iontophoresis: in vitro optimization and human pharmacokinetic data.
    Jadoul A; Mesens J; Caers W; de Beukelaar F; Crabbé R; Préat V
    Pharm Res; 1996 Sep; 13(9):1348-53. PubMed ID: 8893273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iontophoresis and electroporation: comparisons and contrasts.
    Banga AK; Bose S; Ghosh TK
    Int J Pharm; 1999 Mar; 179(1):1-19. PubMed ID: 10053197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Research progress of physical transdermal enhancement techniques in tumor therapy.
    Han W; Liu F; Liu G; Li H; Xu Y; Sun S
    Chem Commun (Camb); 2023 Mar; 59(23):3339-3359. PubMed ID: 36815500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absorption of iontophoresis-driven 2% lidocaine with epinephrine in the tissues at 5 mm below the surface of the skin.
    Draper DO; Coglianese M; Castel C
    J Athl Train; 2011; 46(3):277-81. PubMed ID: 21669097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-invasive drug delivery technology: development and current status of transdermal drug delivery devices, techniques and biomedical applications.
    Akhtar N; Singh V; Yusuf M; Khan RA
    Biomed Tech (Berl); 2020 May; 65(3):243-272. PubMed ID: 31926064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iontophoretic drug delivery using the IOMED Phoresor system.
    Fischer GA
    Expert Opin Drug Deliv; 2005 Mar; 2(2):391-403. PubMed ID: 16296762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin.
    Nolan LM; Corish J; Corrigan OI; Fitzpatrick D
    Int J Pharm; 2007 Aug; 341(1-2):114-24. PubMed ID: 17502130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breaking the skin barrier: achievements and future directions.
    Zhang H; Zhai Y; Yang X; Zhai G
    Curr Pharm Des; 2015; 21(20):2713-24. PubMed ID: 25925124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reverse iontophoresis for non-invasive transdermal monitoring.
    Leboulanger B; Guy RH; Delgado-Charro MB
    Physiol Meas; 2004 Jun; 25(3):R35-50. PubMed ID: 15253111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of transdermal potential difference during iontophoretic drug delivery.
    Bandrivskyy A; Bernjak A; McClintock PV; Stefanovska A
    IEEE Trans Biomed Eng; 2004 Sep; 51(9):1683-5. PubMed ID: 15376518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.